Ország: Kanada
Nyelv: angol
Forrás: Health Canada
FAMCICLOVIR
PHARMASCIENCE INC
J05AB09
FAMCICLOVIR
250MG
TABLET
FAMCICLOVIR 250MG
ORAL
30/100
Prescription
NUCLEOSIDES AND NUCLEOTIDES
Active ingredient group (AIG) number: 0127885001; AHFS:
APPROVED
2006-11-17
_ _ _pms-FAMCICLOVIR Product Monograph_ _Page 1 of 28 _ PRODUCT MONOGRAPH Pr PMS-FAMCICLOVIR Famciclovir Film-Coated Tablets 125 mg, 250 mg and 500 mg ANTIVIRAL AGENT PHARMASCIENCE INC. 6111 Royalmount Ave., Suite 100 Montréal, Québec H4P 2T4 www.pharmascience.com DATE OF REVISION: November 15, 2016 SUBMISSION CONTROL NO: 199892 _ _ _pms-FAMCICLOVIR Product Monograph_ _Page 2 of 28 _ TABLE OF CONTENTS PART I: HEALTH PROFESSIONAL INFORMATION ............................................................................................ 3 SUMMARY PRODUCT INFORMATION ................................................................................................................... 3 INDICATIONS AND CLINICAL USE ......................................................................................................................... 3 CONTRAINDICATIONS .............................................................................................................................................. 4 WARNINGS AND PRECAUTIONS ............................................................................................................................ 4 ADVERSE REACTIONS .............................................................................................................................................. 5 DRUG INTERACTIONS ............................................................................................................................................... 8 DOSAGE AND ADMINISTRATION ........................................................................................................................... 9 ACTION AND CLINICAL PHARMACOLOGY ....................................................................................................... 11 STORAGE AND STABILITY .................................................................................................................................... 13 DOSAGE FORMS, COMPOSITION AND PACKAGING ........................................................................... Olvassa el a teljes dokumentumot